Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

Nicola Capasso,Agostino Nozzolillo,Giulia Scalia,Roberta Lanzillo,Antonio Carotenuto,Marcello De Angelis,Martina Petruzzo,Francesco Saccà,Cinzia Valeria Russo,Vincenzo Brescia Morra,Marcello Moccia

Multiple Sclerosis and Related Disorders（2021）

引用 24|浏览9

暂无评分

摘要

•Rituximab and ocrelizumab have a similar effect on B-lymphocyte depletion•T lymphocyte reduction is more pronounced in ocrelizumab, when compared with rituximab•There could be a broader immunomodulatory effect for the humanised antibody•A larger, prospective randomised clinical trial is needed

查看译文

关键词

Multiple sclerosis,Rituximab,Ocrelizumab,Lymphocytes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要